A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Adebrelimab (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 26 Jun 2025 New trial record